AU2017264825B2 - CD200 mutant and its uses - Google Patents

CD200 mutant and its uses Download PDF

Info

Publication number
AU2017264825B2
AU2017264825B2 AU2017264825A AU2017264825A AU2017264825B2 AU 2017264825 B2 AU2017264825 B2 AU 2017264825B2 AU 2017264825 A AU2017264825 A AU 2017264825A AU 2017264825 A AU2017264825 A AU 2017264825A AU 2017264825 B2 AU2017264825 B2 AU 2017264825B2
Authority
AU
Australia
Prior art keywords
val
thr
leu
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017264825A
Other languages
English (en)
Other versions
AU2017264825A1 (en
Inventor
Jonathan HEAL
Philip Huxley
Joseph SHERIDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ducentis Biotherapeutics Ltd
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of AU2017264825A1 publication Critical patent/AU2017264825A1/en
Application granted granted Critical
Publication of AU2017264825B2 publication Critical patent/AU2017264825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2017264825A 2016-05-10 2017-05-10 CD200 mutant and its uses Active AU2017264825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608197.8 2016-05-10
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (2)

Publication Number Publication Date
AU2017264825A1 AU2017264825A1 (en) 2018-11-15
AU2017264825B2 true AU2017264825B2 (en) 2021-04-08

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017264825A Active AU2017264825B2 (en) 2016-05-10 2017-05-10 CD200 mutant and its uses

Country Status (14)

Country Link
US (1) US11203628B2 (cg-RX-API-DMAC10.html)
EP (1) EP3455247A1 (cg-RX-API-DMAC10.html)
JP (1) JP6997767B2 (cg-RX-API-DMAC10.html)
KR (2) KR102498901B1 (cg-RX-API-DMAC10.html)
CN (1) CN109219614B (cg-RX-API-DMAC10.html)
AU (1) AU2017264825B2 (cg-RX-API-DMAC10.html)
CA (1) CA3023601A1 (cg-RX-API-DMAC10.html)
EA (1) EA201892554A1 (cg-RX-API-DMAC10.html)
GB (1) GB201608197D0 (cg-RX-API-DMAC10.html)
IL (1) IL262846B2 (cg-RX-API-DMAC10.html)
MX (1) MX386295B (cg-RX-API-DMAC10.html)
SG (1) SG11201809677XA (cg-RX-API-DMAC10.html)
WO (1) WO2017194941A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807079B (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
EP4519297A1 (en) * 2022-05-06 2025-03-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119522234A (zh) * 2022-05-06 2025-02-25 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1032662E (pt) * 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1171154A2 (en) * 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
CA2402293A1 (en) * 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002223338B2 (en) * 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2008089022A2 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
CN102448982B (zh) * 2009-03-31 2018-04-20 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HATHERLEY DEBORAH ET AL, "Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution", STRUCTURE (CAMBRIDGE), (2013-05), vol. 21, no. 5, ISSN 0969-2126, pages 820 - 832 *

Also Published As

Publication number Publication date
KR102689460B1 (ko) 2024-07-26
KR20230025937A (ko) 2023-02-23
BR112018073280A2 (pt) 2019-03-19
IL262846B (en) 2022-10-01
NZ747665A (en) 2025-10-31
ZA201807079B (en) 2019-07-31
CN109219614A (zh) 2019-01-15
SG11201809677XA (en) 2018-11-29
MX386295B (es) 2025-03-18
US20190367580A1 (en) 2019-12-05
EA201892554A1 (ru) 2019-04-30
JP6997767B2 (ja) 2022-03-04
EP3455247A1 (en) 2019-03-20
IL262846B2 (en) 2023-02-01
KR20190003761A (ko) 2019-01-09
KR102498901B1 (ko) 2023-02-10
JP2019518788A (ja) 2019-07-04
CN109219614B (zh) 2022-05-24
US11203628B2 (en) 2021-12-21
GB201608197D0 (en) 2016-06-22
IL262846A (en) 2018-12-31
AU2017264825A1 (en) 2018-11-15
WO2017194941A1 (en) 2017-11-16
CA3023601A1 (en) 2017-11-16
MX2018013778A (es) 2019-08-01

Similar Documents

Publication Publication Date Title
US11203628B2 (en) CD200 mutants and its uses
JP2021522835A (ja) 二機能性結合ポリペプチド
TW202228790A (zh) 用於長效經眼遞送之非共價蛋白質-玻尿酸結合物
US20260116946A1 (en) Novel cd200 fusion proteins
US20250026805A1 (en) Novel proteins
JP2024544972A (ja) Sirp1a及びcd40lベースのキメラタンパク質
US20230272026A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
US20260116951A1 (en) Novel cd200 fusion proteins
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
BR112018073280B1 (pt) Proteína cd200 mutada, proteína de fusão compreendendo a mesma, composição farmacêutica e uso das referidas proteínas ou composição para o tratamento de doença autoimune
EA042608B1 (ru) Мутант cd200 и его применения
JP2026516066A (ja) Cd200融合タンパク質
CN116761634A (zh) 用于长效眼部递送的非共价蛋白质-透明质酸缀合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)